Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 9/20 | 0.54 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.53 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.50 |
| ▸ | QPCT | Q16769 | 1/20 | 0.47 |
| ▸ | FDPS | P14324 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10928841 | 0.90 | TBXAS1 (0.59) | TBXAS1CYP19A1QPCT | |
| SCHEMBL11728012 | 0.87 | TBXAS1 (0.68) | TBXAS1QPCT | |
| SCHEMBL11725061 | 0.87 | TBXAS1 (0.68) | TBXAS1QPCT | |
| SCHEMBL27951984 | 0.85 | TBXAS1 (0.56) | TBXAS1CYP19A1EGLN3CYP1A2CYP3A4 | |
| SCHEMBL439530 | 0.85 | TBXAS1 (0.56) | TBXAS1CYP19A1EGLN3QPCT | |
| Hydrochloric Acid SCHEMBL18318545 | 0.83 | TBXAS1 (0.54) | TBXAS1CYP19A1EGLN3QPCT | |
| Water SCHEMBL28290667 | 0.83 | TBXAS1 (0.54) | TBXAS1CYP19A1EGLN3QPCT | |
| Bromide SCHEMBL29287563 | 0.83 | TBXAS1 (0.54) | TBXAS1CYP19A1EGLN3QPCT | |
| SCHEMBL29007250 | 0.82 | TBXAS1 (0.52) | TBXAS1CYP19A1EGLN3CYP1A2CYP3A4 | |
| SCHEMBL2849098 | 0.82 | TBXAS1 (0.52) | TBXAS1CYP19A1EGLN3QPCT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7314701-B2 | Radiation-sensitive resin composition | JSR CORPORATION (JP) | 2008-01-01 | — | — | US | claimed |
| US-20230287021-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING | PROTEGO BIOPHARMA, INC. | 2023-09-14 | — | — | US | disclosed |
| US-20230287021-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING | PROTEGO BIOPHARMA, INC. | 2023-09-14 | — | — | US | disclosed |
| US-20230287021-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING | PROTEGO BIOPHARMA, INC. | 2023-09-14 | — | — | US | disclosed |
| EP-4097092-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING | Protego Biopharma, Inc. (US) | 2022-12-07 | — | — | EP | disclosed |
| CN-115298168-A | Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | 普罗泰格生物制药公司 | 2022-11-04 | — | — | CN | disclosed |
| WO-2021154842-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING | PROTEGO BIOPHARMA, INC. (US) | 2021-08-05 | — | — | WO | disclosed |
| WO-2021154842-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING | PROTEGO BIOPHARMA, INC. (US) | 2021-08-05 | — | — | WO | disclosed |
| EP-2173740-A1 | HEME-OXYGENASE INHIBITORS AND USE OF THE SAME IN THE TREATMENT OF CANCER AND DISEASES OF THE CENTRAL NERVOUS SYSTEM | Osta Biotechnologies (CA) | 2010-04-14 | — | — | EP | disclosed |
| US-20090176831-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | OSTA BIOTECHNOLOGIES (CA) | 2009-07-09 | — | — | US | disclosed |
| WO-2008151437-A1 | HEME-OXYGENASE INHIBITORS AND USE OF THE SAME IN THE TREATMENT OF CANCER AND DISEASES OF THE CENTRAL NERVOUS SYSTEM | OSTA BIOTECHNOLOGIES (CA) | 2008-12-18 | — | — | WO | disclosed |
| US-7314701-B2 | Radiation-sensitive resin composition | JSR CORPORATION (JP) | 2008-01-01 | — | — | US | disclosed |
| US-20050095527-A1 | Radiation-sensitive resin composition | JSR CORPORATION (JP) | 2005-05-05 | — | — | US | disclosed |
| EP-0104300-B1 | DIAZOLYL ALKANOLES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTIMYCOTIC AGENTS | BAYER AG (DE) | 1986-03-26 | — | — | EP | disclosed |
| US-4518607-A | FUNGICIDES, BACXTERICIDES AND ANTIPROTOZOA AGENTS | SYNTEX (U.S.A.) INC. (US) | 1985-05-21 | — | — | US | disclosed |
| EP-0104300-A1 | Diazolyl alkanoles, process for their preparation and their use as antimycotic agents | BAYER AG (DE) | 1984-04-04 | — | — | EP | disclosed |
| US-4229459-A | Combating fungi with 1-azol-1-yl-1-phenoxy-2-alkane ethers | BAYER AKTIENGESELLSCHAFT (DE) | 1980-10-21 | — | — | US | disclosed |
| US-4059705-A | FUNGICIDE, BACTERICIDE, ANTIPROTOZOA | SYNTEX (U.S.A.) INC. (US) | 1977-11-22 | — | — | US | disclosed |
| US-4045568-A | FUNGICIDES, BACTERICIDES, ANTIPROTOZOA AGENTS | SYNTEX (U.S.A.) INC. (US) | 1977-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230287021-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING | TTR, TTPA, TNNC1 | TBXAS1 2166/4885CYP19A1 4794/4885EGLN3 2832/4885 |
| US-20090176831-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | HMOX1, HMOX2, CYC1 | TBXAS1 1257/4885CYP19A1 614/4885EGLN3 348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.